Children with X-linked hypophosphatemia derive similar benefits from burosumab regardless of whether they start treatment before or after the age of 5 years, shows a post-hoc analysis of a randomised trial.
Rickets results from impaired mineralisation of the growth plate. Hypophosphataemia is common to all forms of rickets as hypophosphataemia impairs both hydroxyapatite formation and failure of apoptosis of the hypertrophied chondrocytes.
Programme Director Professor Martin Savage is joined by experts to present and discuss the application of precision medicine in endocrine disorders, offering clinical expertise and insight, evidence and opinion on this topic.
An international expert group has published recommendations for the monitoring of bone mineral density in child, adolescent and young adult survivors of cancer.
Researchers find that teenagers with endocrine disorders often have gaps in their knowledge of their condition and how to manage it, making them poorly prepared for transition to adult clinic.
The C-type natriuretic peptide analogue vosoritide significantly increases the growth rate of children with achondroplasia, indicate the results of a randomised, double-blind phase 3 study published in The Lancet.
Factors including age at diagnosis and the specific disease influence the likelihood of children with chronic endocrine conditions being lost to follow-up, show French study findings.
Daily treatment with subcutaneous vosoritide leads to a sustained increase in annualised growth velocity, with generally mild side effects, in children with achondroplasia, show data published in The New England Journal of Medicine.
Researchers advise annual screening for tumours in children with mutations in the SDHB gene, starting from the age of 5 years.
Burosumab treatment improves rickets and prevents decline in growth in young children with X-linked hypophosphataemia, show the findings of an open-label phase II study.
